Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Comprehensive Loss

v2.4.0.8
Consolidated Statements of Comprehensive Loss (USD $)
In Thousands, except Share data, unless otherwise specified
12 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Revenues    
Product $ 10,894 $ 12,897
Product licensing fees 1,829 1,686
Service 945 869
Total revenues 13,668 15,452
Cost of revenues    
Product 4,510 3,976
Service 761 733
Total cost of revenues 5,271 4,709
Gross profit 8,397 10,743
Operating expenses    
Research and development 2,887 2,223
Selling, general and administrative 11,561 11,894
Total operating expenses 14,448 14,117
Loss from operations (6,051) (3,374)
Interest expense (1,058) (1,107)
Interest income 1 7
Gain due to change in fair value of common stock (See Note 10) 1,357 (1,599)
Gain on deconsolidation of Ruthigen 11,133 0
Loss due to change in fair value of derivative instruments (1,566) 767
Other expense, net (81) (125)
Net income (loss) 3,735 (5,431)
Preferred stock deemed dividend 0 (1,062)
Net income (loss) available to common shareholders 3,735 (6,493)
Earnings (loss) per common share: Basic $ 0.54 $ (1.30)
Earnings (loss) per common share: Diluted $ 0.54 $ (1.30)
Weighted-average number of common shares outstanding: Basic 6,882,000 4,977,000
Weighted-average number of common shares outstanding: Diluted 6,898,000 4,977,000
Other comprehensive income (loss)    
Net income (loss) 3,735 (5,431)
Foreign currency translation adjustments (78) 62
Other comprehensive income (loss) $ 3,657 $ (5,369)